Other News To Note
Tuesday, April 19, 2011
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., said the FDA has accepted for review the company's biologics license application for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD) and granted the company's request for priority review. The target date for an FDA decision on the VEGF Trap-Eye BLA is Aug. 20.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.